Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-ID.
J Infect
January 2025
Département des Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, F-69004 Lyon, France; Centre International de Recherche en Infectiologie (CIRI), Inserm 1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, France.
Introduction: The increase in the population of immunocompromised patients due to advances in management of end-stage diseases and transplants poses challenges in treating infections caused by multi-drug resistant (MDR) pathogens. Cefiderocol (FDC), a siderophore cephalosporin, has shown efficacy against carbapenem-resistant Gram-negative bacteria.
Methods: This retrospective multicentre study investigated the real-world use of FDC in 114 immunocompromised adults treated for MDR infections in 12 French hospitals (June 2020-November 2023).
Comparison of Dual Monoclonal Antibody Therapies for COVID-19 Evolution: A Multicentric Retrospective Study.
Viruses
September 2024
Laboratoire de Virologie, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Assitance Publique-Hôpitaux de Paris, 75013 Paris, France.
Background: Neutralizing antibodies targeting the SARS-CoV-2 Spike protein reduce COVID-19-related risk of hospitalization, particularly in high-risk individuals. The COCOPREV-R study aimed to evaluate and compare clinical outcomes in high-risk SARS-CoV-2 patients treated with dual monoclonal antibody therapies and to identify associated virological factors.
Methods: The COCOPREV-R study retrospectively collected real-world data from high-risk patients receiving Bamlanivimab/Etesevimab or Casirivimab/Imdevimab dual monoclonal antibody therapies (22 February 2021 to 15 June 2021).
Reappraising Cladophialophora bantiana phaeohyphomycosis in France: retrospective nation-based study.
Lancet Microbe
November 2024
Centre Hospitalo-Universitaire Régional de Tours, Department of Parasitology-Mycology-Tropical Medicine, Tours, France. Electronic address:
Article Synopsis
- * This study analyzed cases of C bantiana infections in France and its territories, involving patients who were diagnosed through a comprehensive surveillance program, focusing on survival rates and the presence of central nervous system (CNS) involvement.
- * Out of 23 patients identified from 2002 to 2022, 65% had CNS involvement, with a notable increase in cases reported in 2022, indicating a possible correlation with environmental factors like rising temperatures.
[An invasive cutaneous aspergillosis during a granulomatosis with polyangiitis].
Rev Med Interne
November 2024
Service de médecine interne, CHU de Saint-Étienne, hôpital Nord, Saint-Étienne, France. Electronic address:
Article Synopsis
- - Aspergillosis is a serious infection that can occur in individuals with weakened immune systems, primarily affecting the lungs but sometimes spreading to the skin and other areas in severe cases.
- - A 76-year-old woman with a relapse of a certain autoimmune disease and undergoing immunosuppressive treatment developed skin lesions, which were diagnosed as invasive cutaneous aspergillosis through a biopsy.
- - The patient improved significantly after being treated with voriconazole, highlighting the importance of thorough testing for opportunistic infections in immunocompromised patients presenting with unusual skin symptoms.
Cell wall nanoparticles from hyphae of grown with caspofungin, nikkomycin, or pyroquilon trigger different activation profiles in macrophages.
Microbiol Spectr
November 2024
Univ Coimbra, CNC-UC-Center for Neuroscience and Cell Biology of the University of Coimbra, Coimbra, Portugal.
Article Synopsis
- This study focuses on cell wall nanoparticles (CWNPs) derived from fungal hyphal cell walls to explore how they affect macrophage immune responses.
- CWNPs were produced using various inhibitors, leading to distinct types that showed different impacts on macrophage activation and viability.
- The findings suggest that modifying fungal cell walls results in nanoparticles with unique properties, which may influence immune reactions and therapeutic strategies during antifungal treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!